What FDA Warning Letters Reveal About Data Integrity

Recent FDA warning letters reinforce a consistent regulatory message: data integrity failures are rarely isolated, but instead, they reflect systemic weaknesses in how data are generated, reviewed, controlled, and governed.

In some cases, FDA cited deficiencies related to audit trail review, incomplete data, inadequate system controls, and ineffective Quality Unit oversight. These observations show contraventions to requirements under 21 CFR Parts 211 and 11, as well as FDA guidance on data integrity. An electronic Quality Management System (eQMS) provides a structured way to remediate these issues by embedding controls directly into workflows rather than relying on manual execution, along with tools that provide visibility and clarity to issues so that they can be monitored and remedied.

Audit Trail Review: Embedding a Critical Control

A key observation a recent warning letter was the failure to review audit trails and electronic raw data during batch release. While audit trails may be enabled at the system level for individual instruments or systems, they may not be fully reviewed if they’re not operationalized within quality processes.

An eQMS addresses this by enforcing data review as part of batch disposition. Workflows can be configured so that release cannot proceed without documented verification of data. Audit trails in an eQMS can also be easily accessed, usually in very few clicks, for easy review. This is further enhanced by eQMS that are equipped with electronic batch records (EBR) that can build in review steps before allowing the users to advance the record forward. These workflows assign responsibility to specific roles, apply due dates, and capture electronic signatures that are compliant with 21 CFR Part 11 requirements.

From a technical standpoint, modern eQMS platforms can integrate with laboratory systems or require structured data uploads, allowing reviewers to easily access results and underlying raw data. The result of deploying an eQMS is a consistent, repeatable review process that produces clear inspection evidence.

Procedural Governance and Data Lifecycle Control

Another observation commonly cited by the FDA is the absence of formal procedures governing electronic data review. Without standardized procedures, even well-designed systems can be used inconsistently.

An eQMS strengthens procedural governance by centralizing document control and linking it directly to execution. SOPs stored in eQMS are version-controlled, routed through approval workflows, and subject to periodic review cycles. Often eQMS like ACE will also have training capabilities integrated into the system, ensuring that qualified personnel are prompted to retrain when there are procedural updates. More advanced implementations extend this control across the entire document lifecycle for all record types (not only limited to SOPs) from creation through review and retention—ensuring that each stage is governed by defined procedures, oversight, and audit trails. This level of integration reduces variability and ensures that both data handling and functional practices are consistent and defensible during inspection.

Technical Controls: Securing Data at the System Level

Warning letters often highlight inadequate controls over computerized systems, including risks related to unauthorized data modification. These findings underscore the importance of system-level safeguards.

An eQMS addresses these risks through a combination of role-based access control, secure authentication, and automated audit trails. Users are assigned permissions based on their responsibilities, ensuring that actions such as data entry, review, and approval are appropriately tracked per user. Each user operates under a unique login, enabling full traceability.

In addition, eQMS enforces data integrity by design. Changes to records in an eQMS are automatically logged with timestamps and user identification. Outright deletion of records is typically restricted, and any corrections to records are set to require documented justification. These controls are supported by system validation and 21 CFR Part 11-compliant features, including electronic signatures and secure audit trails. Together, these capabilities ensure that data remain secure, attributable, and reliable.

Enforcing Complete and Contemporaneous Data Capture

In one report, the FDA observed failures to record out-of-specification (OOS) results and maintain complete laboratory records. These issues directly undermine the requirement that data must be complete and contemporaneous.

An eQMS enforces completeness by requiring structured data entry within records. Critical and mandatory fields can be set up so that they must be completed before records can be finalized, and supporting documentation such as raw data files can be mandated. Time-stamped entries ensure that activities are recorded as they occur, rather than retrospectively.

For OOS and deviation management, an eQMS can be used to initiate OOS records with preset workflows when atypical results are entered. The digital workflow ensures that investigations must be completed and approved before batch release can proceed, ensuring that all data are evaluated and appropriately documented. These controls eliminate selective reporting and support adherence to ALCOA+ principles.

Strengthening Quality Unit Oversight Through Visibility

A recurring theme in warning letters is the failure of the Quality Unit to detect and prevent data integrity issues. FDA expects active oversight supported by timely and accurate information.

An eQMS enhances this oversight by providing real-time visibility into quality processes. Dashboards allow the Quality Unit to monitor open investigations, overdue reviews, and training completion status. Automated notifications and escalation mechanisms ensure that delays or high-risk issues are promptly addressed.

In addition, reporting and trending capabilities enable the identification of recurring issues, supporting a more proactive and risk-based approach to quality management. Rather than relying on periodic review, the Quality Unit can continuously monitor system performance and intervene when necessary.

Integration, Traceability, and Inspection Readiness

One of the primary advantages of an eQMS is its ability to integrate quality processes and maintain end-to-end traceability. Records are interconnected, allowing users to trace every document related to a batch from batch records and initial testing through deviations, investigations, and corrective actions.

This interconnected structure supports rapid retrieval of information during inspections. Inspectors can be shown not only the final decision but also the full context in which it was made, including supporting data, review steps, and approvals. By embedding compliance into workflows and maintaining a complete audit trail of all activities, the system enables organizations to demonstrate control in a clear and credible manner.

Lessons from Recent Warning Letters

FDA expectations for data integrity are clear: data must be complete, accurate, secure, and subject to meaningful review. Recent warning letters issued to companies illustrate the consequences of failing to meet these expectations.

An eQMS provides a comprehensive mechanism to address these gaps by embedding technical controls, standardizing processes, and enhancing oversight. When implemented effectively, it transforms quality management into a proactive, integrated system that not only remediates deficiencies but also supports sustained regulatory compliance. If you’d like to learn more about how eQMS can help you pass audits and inspections, speak with one of our experts today to see how ACE has been used to support life sciences companies across the glove.